Get Cash Back and $0 Commissions
+ The Power of TradeStation
Globe Newswire 19-May-2026 8:30 AM
BEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago, IL.
Presentation details are as follows:
Date & Time: Monday, June 1
Session Type: Poster
Session Title: Sarcoma
Poster Number: 376b
Title: A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted 177lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.
Presenter: Noah Federman, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA
Session Type: Publication Only
Session Title: Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile
Title: Real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer.
First Author: Emma Billmyer, The Analysis Group, Boston, MA
Abstract Number: e17126
About Lantheus
Lantheus?is the?leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in?Massachusetts?with offices in New Jersey,?Canada,?Germany,?Sweden,?Switzerland?and the United Kingdom,?Lantheus?has been providing radiopharmaceutical solutions for?70?years. For more information, visit?www.lantheus.com.
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
